A clinical‑stage biotechnology company focused on developing therapies that target microRNA, a class of regulatory RNA molecules involved in gene expression. Its pipeline has concentrated on treatments for kidney and liver diseases, with lead candidates evaluated in clinical trials and collaboration...
No congressional trades have been disclosed for Regulus Therapeutics Inc (RGLS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.